Unique platform designed to engage pro-resolution responses to restore immune homeostasis in inflammatory disorders without broad immuno-suppression. Cambridge, MA, USA, January 22, 2026 – Resolve M Therapeutics, Inc., the biotech aiming to build the world’s first comprehensive pro-resolution platform for target ID, validation and drug discovery for the treatment of inflammatory diseases, has announced its […]
Groundbreaking research using Nucleome MCC technology reveals complex structure of DNA inside living cells at base pair resolution for the first time, pioneering a new approach to identify new drug targets from human genetics Oxford, UK, 6 November 2025 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), an immunology company tackling the root causes of […]
Leverages Kling’s technology to discover hard-to-find, immuno-functional antibodies from immortalized human B cells Accelerating discovery of first-in-class antibodies to transform disease prevention and treatment Amsterdam, NLD – 24 July 2025 – Kling Bio (“Kling” or “the Company”), a biotech company developing antibody-based drugs for cancer and infectious diseases, today announced it has entered into a […]
Awarded in recognition of excellence in research and innovation and contribution to scientific progress Reflects the revolutionary potential of Curve’s gene-encoded Microcycle® platform to unlock the therapeutic potential of intracellular targets Southampton, UK, 25 June 2025 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company building a pipeline of innovative cyclic peptide and […]
Industry and scientific experts in molecular biology, immunology and antibody research appointed to help develop Commit’s BiCE™ technology platform to treat autoimmune disease and cancer Leading antibody expert Janine Schuurman to co-chair Commit’s Scientific Advisory Board alongside Commit’s CEO Mikkel Wandahl Pedersen Joined by Paul Parren, Gavin Thurston, Susan Kalled, and Esper Boel on the […]
